SCHEMBL25508328

SCHEMBL25508328

C=CCCCC(CCCCCCC)OC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(CC=C)C(=O)NC)C(=O)OCC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BIRC2 Q13490 2/20 0.38
CTSK P43235 1/20 0.35
MMP3 P08254 4/20 0.33
MMP9 P14780 4/20 0.33
DAGLA Q9Y4D2 3/20 0.33
DAGLB Q8NCG7 2/20 0.33
MAPT P10636 2/20 0.33
MEN1 O00255 1/20 0.33
NR1I2 O75469 1/20 0.33
ABHD16A O95870 1/20 0.33
LPL P06858 1/20 0.33
LIPC P11150 1/20 0.33
PNLIP P16233 1/20 0.33
CNR1 P21554 1/20 0.33
ACHE P22303 1/20 0.33
FASN P49327 1/20 0.33
KMT2A Q03164 1/20 0.33
PLA2G7 Q13093 1/20 0.33
ABHD12 Q8N2K0 1/20 0.33
ABHD6 Q9BV23 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25508399 0.97 BIRC2 (0.38) BIRC2CTSKMMP3MMP9DAGLA
SCHEMBL23834433 0.91 PLA2G2A (0.39) BIRC2CTSKMMP3MMP9MMP1
SCHEMBL23834434 0.91 PLA2G2A (0.39) BIRC2CTSKMMP3MMP9MMP1
SCHEMBL25508530 0.90 BIRC2 (0.36) BIRC2CTSKMMP3MMP9DAGLA
SCHEMBL23849114 0.89 BIRC2 (0.45) BIRC2MMP3MMP9MMP1
SCHEMBL23833874 0.88 PLA2G2A (0.39) BIRC2CTSKMMP3MMP9MMP1
SCHEMBL23833873 0.88 PLA2G2A (0.39) BIRC2CTSKMMP3MMP9MMP1
SCHEMBL25508405 0.87 BIRC2 (0.45) BIRC2MMP3MMP9MMP1
SCHEMBL23849262 0.87 BIRC2 (0.36) BIRC2CTSKMMP3MMP9DAGLA
SCHEMBL23849171 0.83 CTSK (0.44) BIRC2CTSKDAGLADAGLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151034-A1 PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-18 US disclosed
US-20230151034-A1 PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151034-A1 PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION ASNS, GLUL, GNMT BIRC2 3019/4885CTSK 1842/4885MMP3 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.